In this infographic, we describe various mass spectrometry-based strategies Frontage has successfully applied in the bioanalysis of ADCs for clinical and preclinical studies. Antibody-drug conjugates (ADCs) combine the best of two modalities: toxin efficacy and antibody specificity. The result is an improved therapeutic window with fewer side effects but the bioanalytical requirements for PK analysis also require a multifaceted approach.

Multiple types of assays are needed for the diverse analytes in the matrix samples to have the overall PK profile of the ADCs. Learn how Frontage leverages LC-MS and LBA platforms to address ADC (antibody-drug conjugate) challenges. Frontage can also develop a customized protocol to address your ADC challenges.

With more monoclonal antibody (mAb) drug conjugates (ADC’s) under preclinical development and in clinical studies, comprehensive and reliable pharmacokinetic evaluation of ADC moieties is increasingly demanded. Liquid chromatography coupled to mass spectrometry (LC-MS) methods have served as sensitive, selective, and versatile tools for ADC PK profiling. Presented here are ADC LC-MS methodology approaches used at Frontage.